According to Grandview Research, the hybrid and decentralized clinical trial (DCT) market will be worth more than 12 billion dollars by 2030.

With pharma having discovered the pitfalls of individual solutions, many are building a new clinical trial technology foundation that can better scale according to their needs.

Hear from four top minds across pharma and discover what the next model of clinical conduct looks like, what it does for sites and patients, and why foundational platforms are critical for the future of digital clinical conduct.